On this page
hydrocortisone valerate cream
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Hydrocortisone Valerate | 2 mg/g | 1370754 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 211047-001 | HYDROCORTISONE VALERATE | CREAM | HYDROCORTISONE VALERATE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | November 4, 2021 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251022). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Hydrocortisone valerate cream USP, 0.2% is medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Hydrocortisone valerate cream USP, 0.2% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream USP, 0.2% should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream USP, 0.2% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hydrocortisone valerate cream USP, 0.2% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Hydrocortisone Valerate Cream USP, 0.2% The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited al 1-833-285-4151 or FDA at 1-800-FDA- 1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Hydrocortisone valerate cream USP, 0.2% contain hydrocortisone valerate, 11,21-dihydroxy-17-[(1-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C 26 H 38 O 6 . It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white, crystalline solid, soluble in ethanol and methanol, sparingly soluble in propylene glycol and insoluble in water. Each gram of hydrocortisone valerate cream USP, 0.2% contains 2 mg hydrocortisone valerate in a hydrophilic base composed of carbomer homopolymer type C, dibasic sodium phosphate, methylparaben, sodium lauryl sulfate, polyoxyethylene (100) stearyl ether, stearyl alcohol, white petrolatum, polyoxyl 2 stearyl ether, purified water and propylene glycol. hv-image.jpg
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied hydrocortisone valerate cream USP, 0.2% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone valerate cream USP, 0.2%, is supplied in 15 g (NDC 21922-007-04), 45g (NDC 21922-007-06), 60 g (NDC 21922-007-07) tube sizes. STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Made in France, formulated in India. Mfg. Lic. No. 361 Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C1, Madkaim Industrial Estate, Madkaim, Post Mardol, Ponda, Goa-403 404, India. Distributed by: Encube Ethicals Inc. 200 Meredith Avenue, Suite 202 Durham, NC 27713 USA Rev 04 Rev. 12/23
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71335-2723-1 | 71335-2723 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2723-1) / 60 g in 1 TUBE | July 29, 2025 |
| 71335-2843-1 | 71335-2843 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2843-1) / 15 g in 1 TUBE | October 22, 2025 |
| 72162-2301-4 | 72162-2301 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2301-4) / 45 g in 1 TUBE | December 31, 2022 |
| 72162-2301-6 | 72162-2301 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2301-6) / 60 g in 1 TUBE | December 31, 2022 |
| 21922-007-04 | 21922-007 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-007-04) / 15 g in 1 TUBE | December 31, 2022 |
| 21922-007-06 | 21922-007 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-007-06) / 45 g in 1 TUBE | December 31, 2022 |
| 21922-007-07 | 21922-007 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-007-07) / 60 g in 1 TUBE | December 31, 2022 |
| 71335-2723 | 71335-2723 | Bryant Ranch Prepack | — | December 31, 2022 |
| 71335-2843 | 71335-2843 | Bryant Ranch Prepack | — | December 31, 2022 |
| 72162-2301 | 72162-2301 | Bryant Ranch Prepack | — | December 31, 2022 |
| 21922-007 | 21922-007 | Encube Ethicals, Inc. | — | December 31, 2022 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.